12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Linzess regulatory update

EMA's CHMP issued a positive opinion recommending approval of Constella linaclotide from Almirall and partner Ironwood to treat moderate to severe irritable bowel syndrome with constipation (IBS-C). In August, FDA approved the

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >